HCPLive Network

DEA, Drug Companies Trade Blame for Generic ADHD Drug Shortage

DEA, Drug Companies Trade Blame for Generic ADHD Drug ShortageA widespread shortage of generic drugs in recent months has made life increasingly difficult for patients with attention deficit hyperactivity disorder (ADHD), and many are growing frantic as they are forced to purchase costly brand name drugs instead of scarce generic versions.

The Food and Drug Administration (FDA), drug manufacturing companies, and patients are all blaming the Drug Enforcement Administration (DEA) for the shortages.

“We have reached out to the DEA and told them that there are shortage issues,” Valerie Jensen, associate director of the FDA’s drug shortage program, told the New York Times. “But the quota issues are outside of our area of responsibility.”

The DEA sets manufacturing quotas for drug making companies, which are intended to ensure adequate supplies while preventing drug abuse. The companies are then free to decide how to divide up their quota for ADHD medicines between high-priced brand names and cheaper generics.

Numerous manufacturers are now saying that certain medications are in short supply, all of which can be found on the FDA’s official shortages list. Among the ADHD medications on the list are the generic versions of Adderall (amphetamine mixed salts) and Ritalin (methylphenidate HCl).

The DEA, however, has refused to acknowledge the shortage and has stated that, if there is one, the blame lies with the drug manufacturers and how they choose to break up their quota between generic and brand name drugs. "Any shortage of these products is therefore a result of decisions made by industry regarding manufacturing or distribution," Barbara Carreno, a DEA spokeswoman told Reuters.

The Times article pointed out that Novartis and Shire Pharmaceuticals, which manufacture both brand name ADHD drugs (Ritalin and Adderall XR, respectively) and generic versions, have each allocated much of their quota to their brand name offerings.

“We are working diligently to ensure our supply of these products meets demand, including discussions with DEA regarding our quota levels for these controlled substances,” Kathy Bloomgarden, a spokeswoman for Novartis, told the Times.

Whoever is to blame, the patients who need medication to treat their ADHD are the ones who are suffering, and many worry that the shortages will continue well into the new year.
 
"I am very concerned about the future," Ruth Hughes, chief executive of Children and Adults with Attention Deficit/Hyperactivity Disorder, told Reuters. "No one seems to have much inventory to get us through the months ahead."

It is not clear how much longer certain patients can continue purchasing expensive name brand drugs in the absence of cheaper, more affordable medications. In a study released last November, the drug information company IMS Health estimated that over 80% of drugs impacted by shortages were generic versions. The study also found that 51.5 million prescriptions were written for ADHD drugs in 2010, with a total sales value of $7.42 billion—an 83% increase over the $4.05 billion value of the drugs in 2006.

In October, President Obama issued an executive order directing the FDA to “take action to help further prevent and reduce prescription drug shortages, protect consumers, and prevent price gouging,” according to a White House statement.

Further Reading
A study in rats hints that exposure to dim light at night may make human breast cancer tumors resistant to doxorubicin. The study was presented at the American Association for Cancer Research's International Conference on Frontiers in Cancer Prevention Research, held from Sept. 28 to Oct. 1 in New Orleans.
The risk of medical professional liability claims alleging failure to screen for esophageal cancer is not a reason to screen for esophageal cancer, according to a research letter published in the Oct. 1 issue of the Journal of the American Medical Association.
A patient at Texas Health Presbyterian Hospital has tested positive for the deadly virus.
Kevin Skole, MD is a board-certified gastroenterologist practicing in central New Jersey, part of the gastroenterology division of Princeton Healthcare Affiliated Physicians, a multi-specialty medical practice based out of the University Medical Center of Princeton at Plainsboro (see www.princetonhcs.org). He discusses the increased incidence, risk factors, and prevention of Clostridium Difficile (C. diff) infection.
There is a wide variety of evidence to support benefits of low-fat diets versus low carbohydrate diets and vice versa. As of today, no one can tell us with certainty whether the well-worn dictum "calories in calories out" is really true. The National Weight Control Registry data give us some confidence in recommending that to lose weight most people need to alter their diet to reduce calories, and need to exercise on a near-daily basis.
Cannabis users who acknowledge their problem and report withdrawal symptoms are likely to increase abstinence over a 12-month period, according to research published in the Journal of Addiction Medicine.
Device therapy eligibility requirements are underestimated using 2D echocardiography compared to cardiac magnetic resonance imaging, according to a study from the Netherlands Heart Journal.
More Reading